(Q37607094)

English

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

scientific article published on October 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Europe PubMed Central

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

chronic myeloid leukemia

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

E Jabbour

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Cortes

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

H M Kantarjian

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

6-12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19798095%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

21 January 2018

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of Breast Magnetic Resonance Imaging to Outcome After Breast-Conservation Treatment With Radiation for Women With Early-Stage Invasive Breast Carcinoma or Ductal Carcinoma in Situ

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.193

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37607094&oldid=2200632656"